Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CYCN Cyclerion Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CYCN
Price (delayed)
$3.2784
Market cap
$10.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$6.88M
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates
Highlights
The net income rose by 3.7% since the previous quarter
The company's gross profit rose by 4.1% QoQ
The quick ratio has contracted by 24% from the previous quarter
The equity has contracted by 12% YoY
Key stats
What are the main financial stats of CYCN
Market
Valuations
Earnings
Shares outstanding
3.21M
Market cap
$10.52M
Enterprise value
$6.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
4.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.31
Revenue
$2.08M
Gross profit
$2.08M
Operating income
-$3.47M
Net income
-$2.94M
EBIT
-$3.01M
EBITDA
-$3.01M
Free cash flow
-$3.43M
Per share
Balance sheet
Liquidity
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$1.34
Book value per share
$3.24
Revenue per share
$0.81
TBVPS
$3.85
Total assets
$9.85M
Total liabilities
$1.07M
Debt
$0
Equity
$8.78M
Working capital
$3.43M
Debt to equity
0
Current ratio
4.21
Quick ratio
3.96
Net debt/EBITDA
1.21
Margins
Efficiency
Dividend
EBITDA margin
-144.4%
Gross margin
100%
Net margin
-141.5%
Operating margin
-166.6%
Return on assets
-30.7%
Return on equity
-34%
Return on invested capital
-59.3%
Return on capital employed
-34.2%
Return on sales
-144.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYCN stock price
How has the Cyclerion Therapeutics stock price performed over time
Intraday
3.83%
1 week
4.26%
1 month
30.1%
1 year
9.28%
YTD
1.81%
QTD
31.14%
Financial performance
How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$2.08M
Gross profit
$2.08M
Operating income
-$3.47M
Net income
-$2.94M
Gross margin
100%
Net margin
-141.5%
The operating income has soared by 69% YoY and by 4.4% from the previous quarter
Cyclerion Therapeutics's operating margin has increased by 8% from the previous quarter
Cyclerion Therapeutics's net margin has increased by 7% from the previous quarter
The net income rose by 3.7% since the previous quarter
Price vs fundamentals
How does CYCN's price correlate with its fundamentals
Growth
What is Cyclerion Therapeutics's growth rate over time
Valuation
What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
1.01
P/S
4.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.31
Cyclerion Therapeutics's EPS has increased by 4.1% from the previous quarter
The stock's price to book (P/B) is 41% less than its 5-year quarterly average of 1.7 but 26% more than its last 4 quarters average of 0.8
The equity has contracted by 12% YoY
The revenue is up by 4.1% since the previous quarter
Efficiency
How efficient is Cyclerion Therapeutics business performance
Cyclerion Therapeutics's ROS has increased by 6% from the previous quarter
The return on invested capital has increased by 6% since the previous quarter
Dividends
What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYCN.
Financial health
How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total liabilities has increased by 47% from the previous quarter but it has decreased by 26% YoY
The current ratio has decreased by 28% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has contracted by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.